-
| Exchange | LSE |
|---|---|
| CurrencyCode | GBP |
| ISIN | GB0033360586 |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | 8M |
|---|---|
| PE Ratio | 0.0 |
| Target Price | 50 |
| Beta | 0.63 |
| Dividend Yield | None |
RUA Life Sciences plc, together with its subsidiaries, develops medical devices in Europe, North America, the Middle East, the Asia Pacific, and Africa. It operates through four segments: Biomaterials, Contract Manufacture, Vascular, and Structural Heart. The company acts as the depository of intellectual property and licensing rights to various biostable and implantable polymers, including Elast-Eon and ECSil; and provides sub-contract manufacturing, assembly, packing, and services of medical device, as well as implantable fabric. It also engages in the development and commercialization of bore polymer sealed grafts and soft tissue patches; and development of tri-leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for RUA.LSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026